[1]武珊珊.喜炎平注射液治疗社区获得性肺炎临床疗效的Meta分析[J].医学信息,2018,31(14):64-69.[doi:10.3969/j.issn.1006-1959.2018.14.020]
　WU Shan-shan.Meta-analysis of Clinical Efficacy of Xiyanping Injection in the Treatment of Community-acquired Pneumonia[J].Journal of Medical Information,2018,31(14):64-69.[doi:10.3969/j.issn.1006-1959.2018.14.020]
点击复制

喜炎平注射液治疗社区获得性肺炎临床疗效的Meta分析()
分享到：

医学信息[ISSN:1006-1959/CN:61-1278/R]

卷:
31卷
期数:
2018年14期
页码:
64-69
栏目:
论著
出版日期:
2018-07-15

文章信息/Info

Title:
Meta-analysis of Clinical Efficacy of Xiyanping Injection in the Treatment of Community-acquired Pneumonia
文章编号:
1006-1959（2018）14-0064-06
作者:
武珊珊
天津市西青医院呼吸内科，天津 300380
Author(s):
WU Shan-shan
Department of Respiratory Medicine,Tianjin Xiqing Hospital,Tianjin 300380,China
关键词:
喜炎平注射液; 社区获得性肺炎; 随机对照试验; Meta分析
Keywords:
Key words：Xiyanping injection; Community-acquired pneumonia; Randomized controlled trial; Meta-analysis
分类号:
R563.1
DOI:
10.3969/j.issn.1006-1959.2018.14.020
文献标志码:
A
摘要:
目的 评价喜炎平注射液治疗成人社区获得性肺炎的临床疗效。方法 检索国内外公开发表的有关喜炎平注射液治疗社区获得性肺炎的随机对照试验研究，观察指标包括临床总有效率、咳嗽消失时间、啰音消失时间、退热时间、白细胞计数、降钙素原）、C-反应蛋白。结果 最终纳入13篇文献，Meta分析结果显示：喜炎平注射液组与对照组相比，临床总有效率提高:比值比为4.24,95%置信区间2.93~6.14，P＜0.00001；咳嗽消失时间缩短:加权均数差为-2.67,95CI：-3.91~-1.44，P＜0.0001；啰音消失时间缩短:标准化均数差为-0.91，95%CI：-1.16~-0.66，P＜0.0001；退热时间缩短：WMD为-1.83，95%CI：-2.92~-0.74，P=0.001；WBC水平无明显变化: WMD为-1.14，95%CI：-2.77~0.48，P=0.17；PCT水平降低：SMD为-1.86，95%CI：-3.02~-0.70，P=0.002；CRP水平降低: SMD为-1.86，95%CI：-2.82~-0.89，P=0.0002。结论 在常规西医治疗基础上加用喜炎平注射液治疗CAP可以明显提高患者临床总有效率，缩短咳嗽、啰音、发热持续时间，降低患者体内PCT、CRP水平，但对降低患者体内的WBC，无明显临床意义；喜炎平注射液治疗CAP患者有较好的疗效，且无严重不良反应，值得临床应用。
Abstract:
Abstract：Objective To evaluate the clinical effect of Xiyanping injection in the treatment of adult community-acquired pneumonia.Methods A randomized controlled trial for the treatment of community-acquired pneumonia was published at home and abroad.Observed indicators included total clinical effectiveness,time to cough disappearance,time of disappearance of arpeggios,time to fever, white blood cell count,procalcitonin,and C-reactive protein.Results Finally,13 articles were included. Meta-analysis showed that the total effective rate was improved in the Xiyanping injection group compared with the control group:odds ratio was 4.24,95% confidence interva l2.93~6.14,P<0.00001;cough disappearance time)shortening:the weighted mean difference is -2.67,95CI:-3.91~-1.44,P<0.0001;the arpeggio disappearance time is shortened:the standardized mean difference is -0.91,95%CI:-1.16~-0.66,P<0.0001; The antipyretic time was shortened:WMD was -1.83,95% CI: -2.92~-0.74,P=0.001;WBC level showed no significant change:WMD was -1.14,95% CI:-2.77~0.48,P=0.17;PCT level reduction:SMD was -1.86,95%CI:-3.02~-0.70,P=0.002;CRP level decreased:SMD was -1.86,95% CI:-2.82~-0.89,P=0.0002.Conclusion The treatment of CAP with Xiyanping injection on the basis of routine western medicine treatment can significantly improve the total clinical effective rate,shorten the duration of cough,arpeggios,fever,and reduce the level of PCT,CRP in patients.However,there is no significant clinical significance in reducing WBC.The Xiyanping injection has better curative effect on CAP patients,and has no serious adverse reactions,so it is worthy of clinical application.

参考文献/References:

[1]Gorelik O,Tzur I,Barchel D,et al.A rise in mean platelet volume during hospitalization for community-acquired pneumonia predicts poor prognosis:a retrospective observational cohort study[J].Bmc Pulmonary Medicine,2017,17(1):137. [2]Akhter S,Rizvi N,Bhura S,et al.Management of community acquired pneumonia by Family Physicians[J].Pakistan Journal of Medical Sciences,2017,33(4):783-787. [3]Lowe BS,Muyodi C,Getambu E,et al.Risk factors for community-acquired pneumonia among adults in Kenya:a case-control study[J].Pneumonia,2017,9(1):17. [4]刘静华.阿奇霉素联合喜炎平治疗老年肺炎120例疗效观察[J].武警后勤学院学报(医学版),2013,22(5):423-424. [5]陈瑜.美洛西林钠舒巴坦钠联合喜炎平治疗中老年社区获得性肺炎的疗效观察[J].现代诊断与治疗,2016,27(24):4736-4737. [6]杨维建.美洛西林钠舒巴坦钠联合喜炎平治疗中老年社区获得性肺炎的疗效观察[J].中国民康医学,2013,25(02):10,63. [7]侯文娟.莫西沙星联合喜炎平对老年社区获得性肺炎患者血清炎症因子水平的影响[J].临床研究,2017,25(12):71-72. [8]肖斌,贺作玉.莫西沙星注射液联合喜炎平注射液治疗社区获得性肺炎的临床疗效观察[J].药学研究,2015,34(7):422-424. [9]夏娟,夏莹.头孢曲松联合喜炎平治疗社区获得性肺炎疗效观察[J].中外健康文摘,2014(16):112-113. [10]裴金宝,吴同利,刘欣欣.喜炎平联合抗菌药物治疗50例社区获得性肺炎患者的临床疗效观察[J].医药前沿,2016,6(35):160-161. [11]张挺.喜炎平注射液辅助抗菌药物治疗老年性肺炎临床研究[J].中国继续医学教育,2015(17):206-207. [12] 疏欣杨,韩春生,李得民,等.喜炎平注射液辅助治疗社区获得性肺炎60例临床观察[J].中国中医急症,2013,22(6):1030-1031. [13]帕依扎·哈继木汗.喜炎平注射液联合阿奇霉素治疗老年性肺炎的临床疗效[J].中国药物经济学,2015,10(04):76-77. [14]姚志强,袁维蔚,陈奕涛,等.喜炎平注射液联合头孢哌酮钠舒巴坦钠对老年社区获得性肺炎患者的影响[J].实用心脑肺血管病杂志,2017,25(10):155-157. [15]吕永中.喜炎平注射液佐治社区获得性肺炎的临床效果探讨[J].世界最新医学信息文摘,2015,15(10):100-101. [16]李玉玲.左氧氟沙星注射液联合喜炎平注射液治疗社区获得性肺炎的临床研究[J].中华实验和临床感染病杂志(电子版),2014,8(04):542-544. [17]刘静.喜炎平注射液在感染性疾病中的应用[J].内蒙古中医药,2017,36(12):145-146.

相似文献/References:

[1]赵建美,邵 岩.血必净治疗社区获得性肺炎的研究进展[J].医学信息,2018,31(02):20.[doi:10.3969/j.issn.1006-1959.2018.02.009]
　ZHAO Jian-mei,SHAO Yan.Research Progress of Xuebijing in Treating Community Acquired Pneumonia[J].Journal of Medical Information,2018,31(14):20.[doi:10.3969/j.issn.1006-1959.2018.02.009]
[2]包克珍,许云丽.新生儿社区获得性肺炎的临床特征分析[J].医学信息,2018,31(02):184.[doi:10.3969/j.issn.1006-1959.2018.02.072]
　BAO Ke-zhen,XU Yun-li.Clinical Characteristics of Neonatal Community Acquired Pneumonia[J].Journal of Medical Information,2018,31(14):184.[doi:10.3969/j.issn.1006-1959.2018.02.072]
[3]赵建美,邵 岩,李京津.电脑中频药透对治疗老年社区获得性肺炎的疗效分析[J].医学信息,2018,31(03):146.[doi:10.3969/j.issn.1006-1959.2018.03.052]
　ZHAO Jian-mei,SHAO Yan,LI Jing-jin.Analysis of the Efficacy of Computer Medium Frequency Drug Penetration in the Treatment of Elderly Community-acquired Pneumonia[J].Journal of Medical Information,2018,31(14):146.[doi:10.3969/j.issn.1006-1959.2018.03.052]
[4]曹立杰,杨林瀛,于国云,等.N-末端脑钠肽前体与社区获得性肺炎患者严重程度关系研究[J].医学信息,2018,31(04):1.[doi:10.3969/j.issn.1006-1959.2018.04.001]
　CAO Li-jie,YANG Lin-ying,YU Guo-yun,et al.Study on the Relationship between N-terminal Brain Natriuretic Peptide Precursors and the Severity of Community-acquired Pneumonia[J].Journal of Medical Information,2018,31(14):1.[doi:10.3969/j.issn.1006-1959.2018.04.001]
[5]俞 静,赵 红,金 晶,等.社区获得性肺炎胸部CT中反晕征的初步研究[J].医学信息,2022,35(10):109.[doi:10.3969/j.issn.1006-1959.2022.10.026]
　YU Jing,ZHAO Hong,JIN Jing,et al.Preliminary Study of Reversed Halo Sign in Chest CT of Community-acquired Pneumonia[J].Journal of Medical Information,2022,35(14):109.[doi:10.3969/j.issn.1006-1959.2022.10.026]
[6]徐安林,刘 忠.不同配比的哌拉西林-他唑巴坦治疗 老年性社区获得性肺炎的疗效对比[J].医学信息,2018,31(15):129.[doi:10.3969/j.issn.1006-1959.2018.15.041]
　XU An-lin,LIU Zhong.Comparison of the Efficacy of Different Ratios of Piperacillin-tazobactam in Elderly Community Acquired Pneumoni[J].Journal of Medical Information,2018,31(14):129.[doi:10.3969/j.issn.1006-1959.2018.15.041]
[7]许 俊.慢性阻塞性肺疾病急性加重期与慢性阻塞性肺疾病并发社区获得性肺炎患者的临床对比[J].医学信息,2018,31(22):118.[doi:10.3969/j.issn.1006-1959.2018.22.033]
　XU Jun.Clinical Comparison of Patients with Acute Exacerbation of Chronic Obstructive Pulmonary Disease and Chronic Obstructive Pulmonary Disease Complicated with Community Acquired Pneumonia[J].Journal of Medical Information,2018,31(14):118.[doi:10.3969/j.issn.1006-1959.2018.22.033]
[8]远 颖.成人社区获得性肺炎中医药研究[J].医学信息,2018,31(23):55.[doi:10.3969/j.issn.1006-1959.2018.23.016]
　YUAN Ying.Traditional Chinese Medicine Research on Adult Community Acquired Pneumonia[J].Journal of Medical Information,2018,31(14):55.[doi:10.3969/j.issn.1006-1959.2018.23.016]
[9]陈亚南,陈 赛,毛琦善.青壮年与中老年社区获得性肺炎病原体的对比分析[J].医学信息,2019,32(01):145.[doi:10.3969/j.issn.1006-1959.2019.01.045]
　CHEN Ya-nan,CHEN Sai,MAO Qi-shan.Comparative Analysis of Pathogens of Acquired Pneumonia among Young Adults and Middle-aged and Elderly People[J].Journal of Medical Information,2019,32(14):145.[doi:10.3969/j.issn.1006-1959.2019.01.045]
[10]林振涛.重症社区获得性肺炎的诊治[J].医学信息,2019,32(22):43.[doi:10.3969/j.issn.1006-1959.2019.22.014]
　LIN Zhen-tao.Diagnosis and Treatment of Severe Community Acquired Pneumonia[J].Journal of Medical Information,2019,32(14):43.[doi:10.3969/j.issn.1006-1959.2019.22.014]

更新日期/Last Update: 2018-07-15